First human tests begin for potential ulcerative colitis drug

NCT ID NCT07350577

Summary

This early-stage study aims to check the safety and basic behavior of an experimental drug called ALTB-268 in healthy volunteers. Researchers will give single, increasing doses to 24 healthy adults to monitor for side effects and see how the drug moves through the body. The results will help determine if ALTB-268 is safe enough to test in people with ulcerative colitis in future studies.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ULCERATIVE COLITIS (UC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Syneos Health Clinical Research Services, LLC

    RECRUITING

    Miami, Florida, 33136, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.